Other AR-positive prostate cancer cell lines generally display decreases in HLA expression when compared with immortalized benign controls (Fig. 7C), and cells that maintain AR expression after enza-resistance show increased HLA expression, as evidenced by previous reports (2, 33, 36, 37). The gene discussed is AR; the disease is prostate carcinoma.